Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. 30036739 2018
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE The prospective, randomized, open-label FIRE-3/AIO KRK0306 trial evaluated the first-line therapy of patients with KRAS exon 2 wild-type metastatic colorectal cancer with fluorouracil, folinic acid and irinotecan plus either cetuximab or bevacizumab. 29496069 2018
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC). 28668873 2017
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer. 29285233 2017
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE The CAIRO3 and AIO 0207 trials demonstrated the efficacy of fluoropyrimidine plus bevacizumab (FP+Bev) maintenance treatment in metastatic colorectal cancer (mCRC) patients. 29123255 2017
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. 24816724 2014
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE Tumour samples were retrospectively obtained from 229 patients from a prospective randomised phase III trial of the AIO colorectal study group, comparing CAPOX and FUFOX in mCRC. 25474278 2014
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. 23244709 2013
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. 21960311 2012
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE The AIO KRK-0306 trial compares the efficacy of infusional 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). 22219013 2012
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. 21300933 2011
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression disease BEFREE Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group. 21609932 2011